explore -WSS

explore

author：knowledge 2025-09-02 05:50:16 - browse：25

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Change Healthcare outage fallout shows need for new oversight

explore

WSS

Organ transplantation is at a crossroads. Major reform is needed

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

First U.S. drug developed to treat liver disease MASH is approved

Russian special forces kill a gunman who broke into a private house near Moscow

HIPAA doesn't protect reproductive records from prosecutors

7 of the most gruesome medical devices in history

focus

explore

entertainment

Peter Hotez and the public health issue of online harassment

AbbVie dramatically boosts its spending on lobbying

Continuity nursing helped my family in our darkest PICU moments

John Green on his newest strategy for fighting tuberculosis

Tori Bowie and the unacceptable rates of Black maternal death

Ebola: Gilead Sciences antiviral shows promise as new treatment

At least 13 dead in Texas as scorching temps continue

Ebola: Gilead Sciences antiviral shows promise as new treatment

Virginia high school admissions case could be legal follow

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

focus

First U.S. drug developed to treat liver disease MASH is approved

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Marvel Studios reveals new trailer for 'The Marvels': Watch here

White House launches permanent pandemic office

Ebola: Gilead Sciences antiviral shows promise as new treatment

UCLA team creates talking throat patch for voice disorders

focus

hotspot

explore

entertainment